Aseptic manufacturing expert Paul Gold joins Vanrx Board of Directors

Ex-Pfizer aseptic manufacturing expert Paul Gold joins Vanrx Board of Directors

September 13, 2016 - News

Vanrx Pharmasystems is announcing the appointment of Paul Gold to its Board of Directors. Mr. Gold is an internationally recognized expert in the production of sterile injectable pharmaceuticals.

Gold’s most recent position was Director of Global Aseptic Technology for Pfizer Global Technology Services. After retiring from a 39-year career in the pharmaceutical industry, Mr. Gold founded Pamigo Aseptic, a consultancy focusing on aseptic pharmaceutical manufacturing.

“Paul brings extensive experience in aseptic processing operations to our board of directors. He will help us accelerate the adoption of our technologies for fill-finish and provide critical ‘voice-of-customer’ guidance to maximize the value of our product roadmap. Paul shares Vanrx’s commitment to enabling more companies to efficiently and consistently produce compliant sterile product for the patient,” said Chris Procyshyn, Chief Executive Officer of Vanrx Pharmasystems.

“I’ve been engaged with Vanrx technology since 2009. It has always seemed to me that this is an innovative and practical way to improve sterility assurance. It will be an honor to help guide the Vanrx team toward a future where aseptic processing has been de-risked to the point where terminal sterilization is no longer seen as the preferred way to ensure delivering sterile product to the patient,” said Paul Gold.

Among Mr. Gold’s accomplishments is the co-invention of the Restricted Access Barrier System (RABS), a method for aseptic process separation and protection used globally in drug production facilities. His areas of expertise include sterile suspension processing, formulation development, equipment design, and product and process development for aseptically-produced sterile products.

Gold holds a Master of Science (Synthetic Organic Chemistry) from the University of Wisconsin, and a Bachelor of Science in chemistry from the State University of New York at Albany. He is a member of the International Society for Pharmaceutical Engineering (ISPE) and a past Chairman of the Pharmaceutical 3-A Standards Steering Committee (www.3-a.org), which develops standard for pharmaceutical manufacturing fabricators and end-users.

About Vanrx Pharmasystems

Vanrx Pharmasystems makes the most technologically advanced sterile filling solutions for the pharmaceutical industry. Vanrx fill-finish machines use isolated robotics and machine vision to automate the packaging of injectable drugs into nested vials, syringes, or cartridges. The company was founded by pharmaceutical industry veterans to create the systems needed to make the next generation of innovative therapies. For more information, visit the website Vanrx.com

Articles you may want to read

Deloitte Fast 50™ list names Vanrx the fastest growing technology company in Canada

Deloitte has named Vanrx Pharmasystems as the fastest growing technology company in Canada on its 2018 Technology Fast 50 list. The Fast 50 program celebrates innovation in the form of rapid revenue growth. Vanrx’s revenue growth percentage was 19,342%, placing it first on the overall list.

Go to article



Vanrx hosts first collaborative User Group meeting

Vanrx recently hosted its first User Group meeting, with customers and members of the Matrix Alliance partnership, coming to Whistler for two days of collaborative discussion. The goal being to share information and strategies regarding the implementation of Vanrx’s Aseptic Filling Workcells.

Go to article